Advertisement

Ticagrelor after pharmacological thrombolysis in patients with ST-segment elevation myocardial infarctions: insight from a trial sequential analysis

  • Mohammed OsmanEmail author
  • Babikir Kheiri
  • Amanda Jo Shigle
  • Maryam Saleem
  • Khansa Osman
  • Partho P. Sengupta
  • Jason A. Moreland
Article
  • 40 Downloads

Abstract

Few randomized controlled trials (RCTs) have compared ticagrelor to clopidogrel after thrombolytic therapy in patients with ST-segment elevation myocardial infarction (STEMI). To assess the quality of the current evidence, a trial sequential analysis (TSA) of all the available RCTs was performed. A literature search through electronic databases for relevant RCTs was completed. Trial sequential boundaries were applied to the meta-analysis to guard against statistical error, calculate the information size (IS), and assess the quality of the currently available evidence. The safety outcome was bleeding at 30-days and the efficacy outcome was major adverse cardiovascular events at 30-days. There were 3 RCTs with a total of 3999 patients were included. For the safety and efficacy outcomes, there was no difference between the ticagrelor and clopidogrel groups (RR 0.94; 95% CI 0.56–1.60, p = 0.83) and (RR 0.87; 95% CI 0.49–1.52, p = 0.62), respectively. The corresponding TSA revealed an IS of 20,928 and 37,266 for safety and efficacy outcomes, respectively. The Z-curves for both outcomes failed to cross the conventional boundary of significance and TSA boundary, indicating no statistical difference between the ticagrelor and clopidogrel group and lack of firm evidence from the currently available RCTs to draw conclusion. Based on the current available RCTs, there is not enough evidence to support or refute better outcomes with ticagrelor in patients with STEMI treated with thrombolytics. Larger RCTs with enough power are needed before firm recommendations can be applied.

Keywords

Acute coronary syndrome St-segment elevation myocardial infarction Ticagrelor Clopidogrel Thrombolytics 

Notes

Compliance with ethical standards

Conflict of interest

All the authors declare that they have no conflict of interest.

References

  1. 1.
    O’Gara PT, Kushner FG, Ascheim DD et al (2013) 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 127:e362–e425Google Scholar
  2. 2.
    Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057CrossRefGoogle Scholar
  3. 3.
    Alexopoulos D, Perperis A, Koniari I et al (2015) Ticagrelor versus high dose clopidogrel in ST-segment elevation myocardial infarction patients with high platelet reactivity post fibrinolysis. J Thromb Thrombolysis 40:261–267CrossRefGoogle Scholar
  4. 4.
    Berwanger O, Lopes RD, Moia DDF et al (2019) Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis: TREAT trial. J Am Coll Cardiol 73:2819–2828CrossRefGoogle Scholar
  5. 5.
    Dehghani P, Lavoie A, Lavi S et al (2017) Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI. Am Heart J 192:105–112CrossRefGoogle Scholar
  6. 6.
    Wetterslev J, Jakobsen JC, Gluud C (2017) Trial sequential analysis in systematic reviews with meta-analysis. BMC Med Res Methodol 17:39CrossRefGoogle Scholar
  7. 7.
    Kheiri B, Osman M, Abdalla A et al (2018) Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials. J Thromb Thrombolysis 46:299–303CrossRefGoogle Scholar
  8. 8.
    Damman P, Woudstra P, Kuijt WJ et al (2012) P2Y12 platelet inhibition in clincal practice. J Thromb Thrombolysis 33(2):143–153CrossRefGoogle Scholar
  9. 9.
    Wallentin L (2009) P2Y(12) inhibitors: differences in properties and mechanisms of action and pontentail consequences for clinical use. Eur Heart J 30(16):1964–1977CrossRefGoogle Scholar
  10. 10.
    Bhatt DL, Pollack CV, Weitz JI et al (2019) Antibody-based ticagrelor reversal agent in healthy volunteers. N Engl J Med 380:1825–1833CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Mohammed Osman
    • 1
    Email author
  • Babikir Kheiri
    • 2
  • Amanda Jo Shigle
    • 1
  • Maryam Saleem
    • 1
  • Khansa Osman
    • 3
  • Partho P. Sengupta
    • 1
  • Jason A. Moreland
    • 1
  1. 1.Division of CardiologyWest Virginia University School of MedicineMorgantownUSA
  2. 2.Knight Cardiovascular InstituteOregon Health & Science UniversityPortlandUSA
  3. 3.Michigan State UniversityFlintUSA

Personalised recommendations